The Tempus Platform

We provide complimentary technology that allows providers safe and secure access to clinical reports and cutting-edge research apps. Powered by a rapidly growing library of clinical and genomic data, the Tempus platform is an easy and intuitive way to gain relevant insights by patient or by project.

In about two weeks physicians receive a comprehensive report for each patient that highlights key findings, including potentially actionable treatments and immunotherapy markers that can be immediately translated into cancer patient care.



Clinical Report Key Features:

1 Genomic Alterations

An intuitive and concise presentation of clinically actionable somatic alterations, clinically significant germline variants, and pertinent negatives

2 Immunotherapy Markers

Key decision drivers for immunotherapy including microsatellite instability (MSI), tumor mutational burden (TMB), and PD-L1 and MMR IHC when ordered.

3 Treatment Implications

Therapy options matched to each patient's genomic profile and organized by level of clinical evidence from FDA approved to preclinical.



4 Clinical Trials

Relevant clinical trials based on the patient's molecular profile and the provided clinical information that is pertinent to trial inclusion/exclusion criteria.

5 Gene Descriptions

Additional clinical context for all reported variants.



GERMLINE VARIANT DETAILS — Dwayne Holder | NW-12345-DH6

BRCA2

This patient has a pathogenic germline BRCA2 mutation. Genetic counseling and appropriate cancer screening is recommended for this patient and potentially, affected family members.

chr13:32907447 c.1832C>A p.S611* — Clinical Significance: Pathogenic

TPMT

This patient has a pharmacogenomic variant in the TPMT gene which leads to reduced enzyme activity. People with this variant are at an increased risk for an adverse drug event when treated with azathioprine or other purine analogs.

chr6:18143955 c.238G>C p.A80P — Pharmacogenetic Variant: ● Adverse Event

CLINICAL HISTORY

2018
- Release from Northwestern ICU
  1/5/2018

2017
- Biopsy: Lung
  MRI: Abdomen
  12/29/2017
- Admitted to Northwestern ICU
  12/27/2017
- Started Palbociclib
  Ended Gemcitabine
  5/10/2017
- CT: Chest
  5/12/2017
- Cardiac arrhythmia
  8/24/2017
- Started Gemcitabine
  6/29/2017
- Diagnosis: Pancreatic ductal adenocarcinoma T2 N0 M0
  CT: Chest
  Partial resection
  Northwestern University, Medical Center
  Comorbidity: Diabetes
  6/19/2017

TEMPUS — Electronically Signed By: Timothy Taylor, M.D. | CLIA Number: 14D2194097 | Date Signed: 12/01/2017 | Laboratory Medical Director: Nike Beaubier, MD, FCAP, MGP | Tempus ID #: ABC-1234678 | Pipeline Version: 11.2 | 3/5

6 Clinical History

Patient's clinical history organized into a sequential timeline with highlighted responses and adverse events.



Mobile Accessibility

We're focused on providing accessible and useful insights, so we deliver your results however you prefer — emailed PDF, interactive portal, and now, mobile app. Our app gives you an interactive and in-depth view of your patient's molecular and clinical data whenever convenient, not just when you have the PDF or printed report on hand.

1 Sortable and filterable therapies and trials

2 In-depth gene descriptions paired with matched therapies

3 Quick access to your patient's clinical timeline

4 Easy and secure access from anywhere

600 West Chicago Ave, Suite 510, Chicago, IL 60654 | Tempus.com